Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer

Summary

NO-CUT is a one-stage phase II trial seeking to establish whether an oxaliplatin-based chemotherapy preceding standard neo-adjuvant fluoropyrimidines-based chemo radiotherapy, can safely spare demolitive surgical intervention in patients with operable rectal cancer, without increasing the risk of distant relapse. The trial also has a translational component aimed at establishing whether selected genomic, epigenetic, and transcriptomic markers are predictive of tumor and patient outcome.

Timeline

Start

2018-06-01

Primary completion

2022-10-31

Completion

2023-12-20

Drugs

Indications